Literature DB >> 23013295

Low expression level of phosphatase and tensin homolog deleted on chromosome ten predicts poor prognosis in chronic lymphocytic leukemia.

Zhi-Jian Zou1, Run Zhang, Lei Fan, Li Wang, Cheng Fang, Li-Na Zhang, Shu Yang, Yuan-Yuan Li, Jian-Yong Li, Wei Xu.   

Abstract

Phosphatase and tensin homolog deleted on chromosome ten (PTEN) is one of the best-studied tumor suppressor genes which can promote cell proliferation and contribute to tumorigenesis. This study aimed to investigate the PTEN mRNA (Pm) expression level in patients with chronic lymphocytic leukemia (CLL) and healthy controls, and its correlation with prognostic factors. Quantitative polymerase chain reaction (qPCR) was used to detect Pm expression. Compared to controls, patients with CLL presented a lower expression level of Pm (p < 0.001). In univariate analysis, the expression level of Pm was significantly decreased in patients with Binet C (p < 0.001) and higher level of β2-microglobulin (β2-MG) (p = 0.036), lactate dehydrogenase (LDH) (p = 0.019) and ZAP-70 (p = 0.008). Higher Pm expression level was found in favorable cytogenetic aberrations (p = 0.016) and the group without p53 aberration (p = 0.005). Multivariate analysis showed that advanced Binet stage (p = 0.027) and p53 aberration (p = 0.007) were associated with a low PTEN expression level. Survival analysis showed that low expression of PTEN was associated with shorter time to first treatment (TTFT) (p = 0.040). These results indicate that PTEN might be a new prognostic marker in patients with CLL.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23013295     DOI: 10.3109/10428194.2012.733880

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  9 in total

Review 1.  Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.

Authors:  David S Sanford; William G Wierda; Jan A Burger; Michael J Keating; Susan M O'Brien
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-02-19

2.  Activation of the PI3K/AKT pathway by microRNA-22 results in CLL B-cell proliferation.

Authors:  F Palacios; C Abreu; D Prieto; P Morande; S Ruiz; T Fernández-Calero; H Naya; G Libisch; C Robello; A I Landoni; R Gabus; G Dighiero; P Oppezzo
Journal:  Leukemia       Date:  2014-05-14       Impact factor: 11.528

3.  Reactivating nuclear PTEN to treat CLL.

Authors:  Rosa Bernardi; Paolo Ghia
Journal:  Oncotarget       Date:  2017-05-30

Review 4.  miRNAs in Lymphocytic Leukaemias-The miRror of Drug Resistance.

Authors:  Yordan Sbirkov; Bozhidar Vergov; Nikolay Mehterov; Victoria Sarafian
Journal:  Int J Mol Sci       Date:  2022-04-22       Impact factor: 6.208

5.  miR-26a and miR-214 down-regulate expression of the PTEN gene in chronic lymphocytic leukemia, but not PTEN mutation or promoter methylation.

Authors:  Zhi-Jian Zou; Lei Fan; Li Wang; Ji Xu; Run Zhang; Tian Tian; Jian-Yong Li; Wei Xu
Journal:  Oncotarget       Date:  2015-01-20

6.  Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones.

Authors:  Giovanna Carrà; Cristina Panuzzo; Davide Torti; Guido Parvis; Sabrina Crivellaro; Ubaldo Familiari; Marco Volante; Deborah Morena; Marcello Francesco Lingua; Mara Brancaccio; Angelo Guerrasio; Pier Paolo Pandolfi; Giuseppe Saglio; Riccardo Taulli; Alessandro Morotti
Journal:  Oncotarget       Date:  2017-05-30

7.  Correlation between PTEN gene polymorphism and oral squamous cell carcinoma.

Authors:  Min Liu; Hongning Song; Zaichen Xing; Guo Lu; Junfu Li; Daiyun Chen
Journal:  Oncol Lett       Date:  2019-06-24       Impact factor: 2.967

Review 8.  Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?

Authors:  Chiara Tarantelli; Antonio Lupia; Anastasios Stathis; Francesco Bertoni
Journal:  Int J Mol Sci       Date:  2020-02-05       Impact factor: 5.923

Review 9.  PI3 kinase signaling pathway in hematopoietic cancers: A glance in miRNA's role.

Authors:  Elham Roshandel; Leila Noorazar; Behrouz Farhadihosseinabadi; Mahshid Mehdizadeh; Mohammad Hossein Kazemi; Sayeh Parkhideh
Journal:  J Clin Lab Anal       Date:  2021-03-05       Impact factor: 2.352

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.